yes. ONCS licenses tech from INO, also some of their products were originally INOs but not core to where INO is going, so ONCS took them and gave INO 4 million warrants in ONCS.
they decreased because they bought warrants. may have something to do with the recent weakness in stock price
What I like is how INO addresses issues as they come up. First it was no partners...voila, Roche deal. Then bashers kept harping on lack of institutions. Now INO has taken car of that. Every objection to this stock selling for $20++ is being systematically eliminated by mgt.
so when ONCS gets bought for $6 in December, INO scores another $20 million with no dilution! Genius Dr. Kim, pure genius.
looking good. maybe people buying INO and ONCS are looking for other immunotherapy plays that haven't run up yet!
agree, pursuing same strategy. would like to see ONCS get bought for $6/sh, INO grow to $100+++ per share